Compare Gilead Sciences, Inc. (GILD) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Liberty Global Ltd Class C — how do they compare? Gilead Sciences, Inc. trades at $136.45 (market cap $163.51B), while Liberty Global Ltd Class C trades at $10.43 (market cap $3.61B). The key difference: Gilead Sciences, Inc. is far larger — about 45.3× Liberty Global Ltd Class C's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.
| GILD | LBTYK | |
|---|---|---|
Market Cap | $163.51B | $3.61B |
Sector | Health | Technology |
52-Week High | $155.80 | $12.67 |
52-Week Low | $108.22 | $10.11 |
Enterprise Value | $178.05B | $10.90B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
LBTYK trades at $10.49, up 1.16% with mixed technical signals showing bearish moving averages but oversold RSI. The company reported a significant net loss of -$7.14B in 2025 despite $4.88B revenue, though Q1 2026 showed improvement with a positive EPS beat. Analyst sentiment remains strongly bullish with 69% buy ratings, driven by the planned 2027 Ziggo Group spin-off as a key catalyst.
The stock presents a high-risk opportunity with potential upside from sum-of-the-parts valuation and spin-off catalysts, but faces substantial execution risks given persistent losses and competitive telecom pressures. Current valuation metrics (P/S 0.72, P/B 0.37) suggest deep discount to intrinsic value if restructuring succeeds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
